{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:38:03Z","timestamp":1782135483475,"version":"3.54.5"},"publisher-location":"Cham","reference-count":189,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032228994","type":"print"},{"value":"9783032229007","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/164_2025_784","type":"book-chapter","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T18:36:03Z","timestamp":1769711763000},"page":"177-210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antiplatelet Therapy"],"prefix":"10.1007","author":[{"given":"Richard T.","family":"Amison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon C.","family":"Pitchford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"784_CR1","doi-asserted-by":"crossref","unstructured":"Abo-Aly M, George B, Shokri E, Chelvarajan L, El-Helw M, Smyth SS, et al (2021) Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction. J Thromb Thrombolysis [Internet] [cited 2025 Jul 17];52(3):934\u2013940. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33258102\/","DOI":"10.1007\/s11239-020-02345-8"},{"key":"784_CR2","doi-asserted-by":"crossref","unstructured":"Ahn HS, Foster C, Boykow G, Stamford A, Manna M, Graziano M (2000) Inhibition of cellular action of thrombin by N3-cyclopropyl-7-{[4-(1-methylethyl)phenyl]methyl}-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol [Internet] [cited 2025 Jul 3];60(10):1425\u20131434. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006295200004603?via%3Dihub","DOI":"10.1016\/S0006-2952(00)00460-3"},{"key":"784_CR3","doi-asserted-by":"crossref","unstructured":"Aisiku O, Peters CG, De Ceunynck K, Ghosh CC, Dilks JR, Fustolo-Gunnink SF, et al (2015) Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. Blood [Internet] [cited 2025 Jul 11];125(12):1976\u20131985. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25587041\/","DOI":"10.1182\/blood-2014-09-599910"},{"key":"784_CR4","doi-asserted-by":"crossref","unstructured":"Ajani AE, Lefkovits J (2008) Approaching an age of reason with antiplatelet therapy. Lancet [Internet] [cited 2025 Jul 14];371(9621):1315\u20131316. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0140673608605735","DOI":"10.1016\/S0140-6736(08)60573-5"},{"key":"784_CR5","doi-asserted-by":"crossref","unstructured":"Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, et al (2012) Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv [Internet] [cited 2025 Jul 17];5(6):797\u2013804. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23169985\/","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323"},{"key":"784_CR6","doi-asserted-by":"crossref","unstructured":"Amison RT, Arnold S, O\u2019Shaughnessy BG, Cleary SJ, Ofoedu J, Idzko M, et al (2017) Lipopolysaccharide (LPS) induced pulmonary neutrophil recruitment and platelet activation is mediated via the P2Y 1 and P2Y 14 receptors in mice. Pulm Pharmacol Ther [Internet] [cited 2019 Aug 2];45:62\u201368. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28487256","DOI":"10.1016\/j.pupt.2017.05.005"},{"key":"784_CR7","doi-asserted-by":"crossref","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al (2007) Variability in individual responsiveness to clopidogrel. Clinical implications, management, and future perspectives. J Am Coll Cardiol [Internet] [cited 2025 Jul 17];49(14):1505\u20131516. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17418288\/","DOI":"10.1016\/j.jacc.2006.11.044"},{"key":"784_CR8","doi-asserted-by":"crossref","unstructured":"Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo JF, et al (2012) Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis [Internet] [cited 2025 Jul 17];34(1):44\u201355. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22569899\/","DOI":"10.1007\/s11239-012-0737-3"},{"key":"784_CR9","unstructured":"Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, et al (2008) Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON\u2013TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel\u2013Thrombolysis In Myocardial Infarction) analysis J Am Coll Cardiol [Internet] [cited 2025 Jul 14];51(21):2028\u20132033. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0735109708012709"},{"key":"784_CR10","doi-asserted-by":"crossref","unstructured":"Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, et al (2017) Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med [Internet] [cited 2025 Aug 26];376(5):429\u2013439. Available from: https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa1611770","DOI":"10.1056\/NEJMoa1611770"},{"key":"784_CR11","doi-asserted-by":"crossref","unstructured":"Baldoni D, Bruderer S, Krause A, Gutierrez M, Gueret P, Astruc B, et al (2014) A new reversible and potent P2Y12 receptor antagonist (ACT-246475): tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trial. Clin Drug Investig [Internet] [cited 2025 Jul 17];34(11):807\u2013818. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25331625\/","DOI":"10.1007\/s40261-014-0236-8"},{"issue":"3","key":"784_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0014-2999(01)00733-6","volume":"412","author":"A Baurand","year":"2001","unstructured":"Baurand A, Raboisson P, Freund M, L\u00e9on C, Cazenave JP, Bourguignon JJ et al (2001) Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol [Internet]. 412(3):213\u2013221. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11166284","journal-title":"Eur J Pharmacol [Internet]."},{"key":"784_CR13","doi-asserted-by":"crossref","unstructured":"Belch J, Cormie J, Newman P, McLaren M, Barbenel J, Capell H, et al (1983) Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud\u2019s syndrome: a double-blind trial. Br J Clin Pharmacol [Internet] [cited 2025 Aug 26];15(1 S):113S\u2013116S. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/6337601\/","DOI":"10.1111\/j.1365-2125.1983.tb02119.x"},{"key":"784_CR14","doi-asserted-by":"crossref","unstructured":"Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH (2000) Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation [Internet] [cited 2025 Jul 17];102(6):624\u2013629. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10931801\/","DOI":"10.1161\/01.CIR.102.6.624"},{"issue":"24","key":"784_CR15","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","volume":"361","author":"DL Bhatt","year":"2009","unstructured":"Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G et al (2009) Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361(24):2330\u20132341","journal-title":"N Engl J Med"},{"key":"784_CR16","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Stone GW, Mahaffey KW, Michael Gibson C, Gabriel Steg P, Hamm CW, et al (2013) Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med [Internet] [cited 2025 Jul 17];368(14):1303\u20131313. Available from: https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa1300815","DOI":"10.1056\/NEJMoa1300815"},{"key":"784_CR17","doi-asserted-by":"crossref","unstructured":"Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, et al (2011) Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet [Internet] [cited 2025 Aug 26];377(9782):2013\u20132022. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21616527\/","DOI":"10.1016\/S0140-6736(11)60600-4"},{"key":"784_CR18","doi-asserted-by":"crossref","unstructured":"Brar SS, Ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, et al (2011) Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant data. J Am Coll Cardiol [Internet] [cited 2025 Jul 17];58(19):1945\u20131954. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22032704\/","DOI":"10.1016\/j.jacc.2011.06.059"},{"issue":"3","key":"784_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s002100100463","volume":"364","author":"K Braun","year":"2001","unstructured":"Braun K, Rettinger J, Ganso M, Kassack M, Hildebrandt C, Ullmann H et al (2001) Nf449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors. Naunyn Schmiedebergs Arch Pharmacol 364(3):285\u2013290","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"784_CR20","doi-asserted-by":"crossref","unstructured":"Burnstock G (2007) Purine and pyrimidine receptors. Cell Mol Life Sci [Internet] [cited 2013 Sep 24];64(12):1471\u20131483. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17375261","DOI":"10.1007\/s00018-007-6497-0"},{"issue":"38","key":"784_CR21","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A et al (2023) 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J 44(38):3720\u20133826","journal-title":"Eur Heart J"},{"key":"784_CR22","doi-asserted-by":"crossref","unstructured":"Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, et al (2007) Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non\u2013ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol [Internet] [cited 2025 Jul 17];50(19):1844\u20131851. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0735109707026344","DOI":"10.1016\/j.jacc.2007.07.053"},{"key":"784_CR23","doi-asserted-by":"crossref","unstructured":"Capra V, B\u00e4ck M, Angiolillo DJ, Cattaneo M, Sakariassen KS (2014) Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. J Thromb Haemost [Internet] [cited 2025 Aug 26];12(2):126\u2013137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24298905\/","DOI":"10.1111\/jth.12472"},{"key":"784_CR24","doi-asserted-by":"crossref","unstructured":"Caroff E, Hubler F, Meyer E, Renneberg D, Gnerre C, Treiber A, et al (2015) Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic acid butyl ester (ACT-246475) and its prodrug (ACT-281959), a novel P2Y 12 receptor antagonist with a wider therapeutic window in the rat than clopidogrel. [cited 2025 Jul 10];4\u20136. Available from: https:\/\/pubs.acs.org\/sharingguidelines","DOI":"10.1021\/acs.jmedchem.5b00933"},{"key":"784_CR25","doi-asserted-by":"crossref","unstructured":"Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med [Internet] [cited 2025 Aug 26];345(25):1809\u20131817. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11752357\/","DOI":"10.1056\/NEJMoa003199"},{"key":"784_CR26","doi-asserted-by":"crossref","unstructured":"Cattaneo M (2005) The P2 receptors and congenital platelet function defects. Semin Thromb Hemost [Internet] [cited 2025 Jul 14];31(2):168\u2013173. Available from: http:\/\/www.thieme-connect.de\/products\/ejournals\/html\/10.1055\/s-2005-869522","DOI":"10.1055\/s-2005-869522"},{"key":"784_CR27","doi-asserted-by":"crossref","unstructured":"Cattaneo M (2011) Resistance to anti-platelet agents. Thromb Res [Internet] [cited 2011 Oct 31];127 Suppl:S61\u2013S63. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21262444","DOI":"10.1016\/S0049-3848(11)70017-2"},{"key":"784_CR28","doi-asserted-by":"crossref","unstructured":"Cattaneo M, Faioni EM (2012) Why does ticagrelor induce dyspnea? Thromb Haemost [Internet] [cited 2025 Jul 17];108(6):1031\u20131036. Available from: http:\/\/www.thieme-connect.de\/products\/ejournals\/html\/10.1160\/TH12-08-0547","DOI":"10.1160\/TH12-08-0547"},{"key":"784_CR29","doi-asserted-by":"crossref","unstructured":"Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, et al (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (80- ) [Internet] [cited 2025 Aug 26];296(5567):539\u2013541. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11964481\/","DOI":"10.1126\/science.1068711"},{"key":"784_CR30","doi-asserted-by":"crossref","unstructured":"Chew DP, Bhatt DL, Sapp S, Topol EJ (2001) The online version of this article, along with updated information and services, is located on the World Wide Web at: http:\/\/circ.ahajournals.org\/content\/103\/2\/201. Online. pp 201\u2013206","DOI":"10.1161\/01.CIR.103.2.201"},{"key":"784_CR31","doi-asserted-by":"crossref","unstructured":"Collet J-P, Cuisset T, Rang\u00e9 G, Cayla G, Elhadad S, Pouillot C, et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med [Internet] [cited 2025 Jul 17];367(22):2100\u20132109. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23121439\/","DOI":"10.1056\/NEJMoa1209979"},{"issue":"4","key":"784_CR32","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1055\/s-0037-1613071","volume":"87","author":"L Covic","year":"2002","unstructured":"Covic L, Singh C, Smith H, Kuliopulos A (2002a) Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome. Thromb Haemost 87(4):722\u2013727","journal-title":"Thromb Haemost"},{"key":"784_CR33","doi-asserted-by":"crossref","unstructured":"Covic L, Gresser AL, Talavera J, Swift S, Kuliopulos A (2002b) Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci U S A [Internet] [cited 2025 Jul 11];99(2):643\u2013648. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11805322\/","DOI":"10.1073\/pnas.022460899"},{"key":"784_CR34","doi-asserted-by":"crossref","unstructured":"Cox D (2005) Oral GPIIb \/ IIIa Antagonists: What Went Wrong? Curr Pharm Des [Internet] [cited 2025 Aug 26];10(14):1587\u20131596. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15134557\/","DOI":"10.2174\/1381612043384673"},{"key":"784_CR35","doi-asserted-by":"crossref","unstructured":"Damaskinaki FN, Moran LA, Garcia A, Kellam B, Watson SP (2021) Overcoming challenges in developing small molecule inhibitors for GPVI and CLEC-2. Platelets [Internet] [cited 2025 Aug 26];32(6):744\u2013752. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33406951\/","DOI":"10.1080\/09537104.2020.1863939"},{"key":"784_CR36","doi-asserted-by":"crossref","unstructured":"Damiano BP, Derian CK, Maryanoff BE, Zhang HC, Gordon PA (2003) RWJ-58259: a selective antagonist of protease activated Receptor-1. Cardiovasc Drug Rev [Internet] [cited 2025 Jul 3];21(4):313\u2013326. Available from: \/doi\/pdf\/10.1111\/j.1527-3466.2003.tb00124.x","DOI":"10.1111\/j.1527-3466.2003.tb00124.x"},{"issue":"2","key":"784_CR37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1055\/s-0037-1615690","volume":"85","author":"C Dangelmaier","year":"2001","unstructured":"Dangelmaier C, Jin J, Smith JB, Kunapuli SP (2001) Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway. Thromb Haemost 85(2):341\u2013348","journal-title":"Thromb Haemost"},{"key":"784_CR38","doi-asserted-by":"crossref","unstructured":"Dockendorff C, Aisiku O, Verplank L, Dilks JR, Smith DA, Gunnink SF, et al (2012) Discovery of 1,3-diaminobenzenes as selective inhibitors of platelet activation at the PAR1 receptor. ACS Med Chem Lett [Internet] [cited 2025 Jul 3];3(3):232\u2013237. Available from: \/doi\/pdf\/10.1021\/ml2002696?ref=article_openPDF","DOI":"10.1021\/ml2002696"},{"key":"784_CR39","doi-asserted-by":"crossref","unstructured":"Dovlatova N, Wijeyeratne YD, Fox SC, Manolopoulos P, Johnson AJ, White AE, et al (2008) Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor. Thromb Haemost [Internet] [cited 2016 Jan 12];100(2):261\u2013270. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18690346","DOI":"10.1160\/TH07-10-0601"},{"key":"784_CR40","doi-asserted-by":"crossref","unstructured":"Dowal L, Sim DS, Dilks JR, Blair P, Beaudry S, Denker BM, et al (2011) Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1. Proc Natl Acad Sci U S A [Internet] [cited 2025 Jul 11];108(7):2951\u20132956. Available from: \/doi\/pdf\/10.1073\/pnas.1014863108?download=true","DOI":"10.1073\/pnas.1014863108"},{"key":"784_CR41","doi-asserted-by":"crossref","unstructured":"Duvernay M, Young S, Gailani D, Schoenecker J, Hamm H (2013) Protease-Activated Receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets. Mol Pharmacol [Internet] [cited 2025 Jul 11];83(4):781\u2013792. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0026895X24036824","DOI":"10.1124\/mol.112.083477"},{"key":"784_CR42","doi-asserted-by":"crossref","unstructured":"Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, et al (1974) A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J [Internet] [cited 2025 Aug 26];1(5905):436\u2013440. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/4593555\/","DOI":"10.1136\/bmj.1.5905.436"},{"key":"784_CR43","doi-asserted-by":"crossref","unstructured":"Emilsson OL, Mohammad MA, Grimfj\u00e4rd P, Persson J, Santos-Pardo I, Erlinge D, et al (2025) Cangrelor during percutaneous coronary intervention in patients with cardiogenic shock or cardiac arrest. JACC Cardiovasc Interv [Internet] [cited 2025 Jul 17];18(7):853\u2013862. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1936879825007897","DOI":"10.1016\/j.jcin.2025.01.451"},{"key":"784_CR44","doi-asserted-by":"crossref","unstructured":"Fabre JE, Nguyen MT, Athirakul K, Coggins K, McNeish JD, Austin S, et al (2001) Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest [Internet] [cited 2025 Aug 26];107(5):603\u2013610. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11238561\/","DOI":"10.1172\/JCI10881"},{"key":"784_CR45","doi-asserted-by":"crossref","unstructured":"Faruqi TR, Weiss EJ, Shapiro MJ, Huang W, Coughlin SR (2000) Structure-function analysis of protease-activated receptor 4 tethered ligand peptides: determinants of specificity and utility in assays of receptor function. J Biol Chem [Internet] [cited 2025 Jul 14];275(26):19728\u201319734. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0021925819800431","DOI":"10.1074\/jbc.M909960199"},{"key":"784_CR46","doi-asserted-by":"crossref","unstructured":"FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Lawson JA, et al (1983) Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest [Internet] [cited 2025 Aug 26];71(3):676\u2013688. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/6338043\/","DOI":"10.1172\/JCI110814"},{"key":"784_CR47","doi-asserted-by":"crossref","unstructured":"Flaumenhaft R, De Ceunynck K (2017) Targeting PAR1: now what? Trends Pharmacol Sci [Internet] [cited 2025 Jul 11];38(8):701. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5580498\/","DOI":"10.1016\/j.tips.2017.05.001"},{"key":"784_CR48","doi-asserted-by":"crossref","unstructured":"Fontayne A, Meiring M, Lamprecht S, Roodt J, Demarsin E, Barbeaux P, et al (2008) The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb Haemost [Internet] [cited 2025 Aug 26];100(4):670\u2013677. Available from: http:\/\/www.thieme-connect.com\/products\/ejournals\/html\/10.1160\/TH08-02-0073","DOI":"10.1160\/TH08-02-0073"},{"key":"784_CR49","doi-asserted-by":"crossref","unstructured":"French SL, Arthur JF, Lee H, Nesbitt WS, Andrews RK, Gardiner EE, et al (2016a) Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood. J Thromb Haemost [Internet] [cited 2025 Jul 11];14(8):1642\u20131654. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1538783622035231","DOI":"10.1111\/jth.13293"},{"key":"784_CR50","doi-asserted-by":"crossref","unstructured":"French SL, Arthur JF, Lee H, Nesbitt WS, Andrews RK, Gardiner EE, et al (2016b) Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood. J Thromb Haemost [Internet] [cited 2025 Jul 14];14(8):1642\u20131654. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26878340\/","DOI":"10.1111\/jth.13293"},{"key":"784_CR51","doi-asserted-by":"crossref","unstructured":"French SL, Thalmann C, Bray PF, Macdonald LE, Murphy AJ, Sleeman MW, et al (2018) A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant. Blood Adv [Internet] [cited 2025 Jul 3];2(11):1283\u20131293. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29884748\/","DOI":"10.1182\/bloodadvances.2017015552"},{"key":"784_CR52","doi-asserted-by":"crossref","unstructured":"Fung CYE, Cendana C, Farndale RW, Mahaut-smith MP (2007) Primary and secondary agonists can use P2X1 receptors as a major pathway to increase intracellular Ca2+ in the human platelet. J Thromb Haemost [Internet] [cited 2025 Jul 14];5(5):910\u2013917. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S153878362210437X","DOI":"10.1111\/j.1538-7836.2007.02525.x"},{"key":"784_CR53","doi-asserted-by":"crossref","unstructured":"Gachet C (2008) P2 receptors, platelet function and pharmacological implications. Thromb Haemost [Internet] [cited 2011 Sep 6];99(3):466\u2013472. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18327393","DOI":"10.1160\/TH07-11-0673"},{"key":"784_CR54","doi-asserted-by":"crossref","unstructured":"Gibbins JM, Okuma M, Farndale R, Barnes M, Watson SP (1997) Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor \u03b3-chain. FEBS Lett [Internet] [cited 2025 Aug 26];413(2):255\u2013259. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9280292\/","DOI":"10.1016\/S0014-5793(97)00926-5"},{"key":"784_CR55","doi-asserted-by":"crossref","unstructured":"Gieseler F, Ungefroren H, Settmacher U, Hollenberg MD, Kaufmann R (2013) Proteinase-activated receptors (PARs) - Focus on receptor-receptor- interactions and their physiological and pathophysiological impact. Cell Commun Signal [Internet] [cited 2025 Jul 11];11(1):1\u201326. Available from: https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/1478-811X-11-86","DOI":"10.1186\/1478-811X-11-86"},{"key":"784_CR56","doi-asserted-by":"crossref","unstructured":"Goggs R, Williams CM, Mellor H, Poole AW (2015) Platelet Rho GTPases\u2013a focus on novel players, roles and relationships. Biochem J [Internet] [cited 2025 Jul 11];466(3):431\u2013442. Available from: https:\/\/www.sciencedirect.com\/org\/science\/article\/pii\/S1470872815002003","DOI":"10.1042\/BJ20141404"},{"issue":"2","key":"784_CR57","doi-asserted-by":"publisher","first-page":"156","DOI":"10.5551\/jat.3038","volume":"17","author":"S Goto","year":"2010","unstructured":"Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P (2010a) Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 17(2):156\u2013164","journal-title":"J Atheroscler Thromb"},{"key":"784_CR58","doi-asserted-by":"publisher","unstructured":"Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL (2010b) Double-blind, placebo-controlled phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J [Internet] cited 2025 Jul 3];31(21):2601\u20132613. Available from: https:\/\/doi.org\/10.1093\/eurheartj\/ehq320","DOI":"10.1093\/eurheartj\/ehq320"},{"key":"784_CR59","doi-asserted-by":"crossref","unstructured":"Gratacap MP, Herault JP, Viala C, Ragab A, Savi P, Herbert JM, et al (2000) Fc\u03b3RIIA requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization, and platelet aggregation. Blood [Internet] [cited 2025 Jul 14];96(10):3439\u20133446. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497120482825","DOI":"10.1182\/blood.V96.10.3439.h8003439_3439_3446"},{"key":"784_CR60","doi-asserted-by":"crossref","unstructured":"Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC, et al (2006) Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J [Internet] [cited 2025 Jul 17];151(3):689.e1\u2013689.e10. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0002870305010458?casa_token=Rpxzh9EmGY4AAAAA:z-1w56zsGUpo5aLejYN_Q1S6SCcg_ksCUaI3emaUN17uHCS6EpIwueazYXeYI72_KZGpKRFTbA","DOI":"10.1016\/j.ahj.2005.11.014"},{"key":"784_CR61","doi-asserted-by":"crossref","unstructured":"Greenbaum AB, Ohman EM, Gibson CM, Borzak S, Stebbins AL, Lu M, et al (2007) Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the safety, tolerability and effect on patency in acute myocardial infarction (STEP-AMI) angiographic trial. Am Heart J [Internet] [cited 2025 Jul 17];154(4):702\u2013709. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0002870307004929","DOI":"10.1016\/j.ahj.2007.06.001"},{"key":"784_CR62","doi-asserted-by":"crossref","unstructured":"Gresele P, Momi S (2022) Novel approaches to antiplatelet therapy. Biochem Pharmacol [Internet] [cited 2025 Aug 26];206. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36243098\/","DOI":"10.1016\/j.bcp.2022.115297"},{"key":"784_CR63","doi-asserted-by":"crossref","unstructured":"Gryka RJ, Buckley LF, Anderson SM (2017) Vorapaxar: the current role and future directions of a novel protease-activated receptor antagonist for risk reduction in atherosclerotic disease. Drugs R D [Internet] [cited 2025 Jul 11];17(1):65. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5318326\/","DOI":"10.1007\/s40268-016-0158-4"},{"key":"784_CR64","doi-asserted-by":"crossref","unstructured":"Habib A, Fitzgerald GA, Maclouf J (1999) Phosphorylation of the thromboxane receptor \u03b1, the predominant isoform expressed in human platelets. J Biol Chem [Internet] [cited 2025 Aug 26];274(5):2645\u20132651. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9915793\/","DOI":"10.1074\/jbc.274.5.2645"},{"key":"784_CR65","doi-asserted-by":"crossref","unstructured":"Hagihara K, Kazui M, Kurihara A, Iwabuchi H, Ishikawa M, Kobayashi H, et al (2010) Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite. Drug Metab Dispos [Internet] [cited 2025 Jul 17];38(6):898\u2013904. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0090955624023730","DOI":"10.1124\/dmd.110.032086"},{"key":"784_CR66","doi-asserted-by":"crossref","unstructured":"Halkes PH, Van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A (2006) Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet [Internet] [cited 2025 Aug 26];367(9523):1665\u20131673. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16714187\/","DOI":"10.1016\/S0140-6736(06)68734-5"},{"key":"784_CR67","doi-asserted-by":"crossref","unstructured":"Han X, Nieman MT (2018) PAR4 (Protease-Activated Receptor 4): PARticularly Important 4 Antiplatelet Therapy Arterioscler Thromb Vasc Biol [Internet] [cited 2025 Jul 11];38(2):287\u2013289. Available from: \/doi\/pdf\/10.1161\/ATVBAHA.117.310550?download=true","DOI":"10.1161\/ATVBAHA.117.310550"},{"key":"784_CR68","doi-asserted-by":"crossref","unstructured":"Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, et al (2009) Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med [Internet] [cited 2025 Jul 17];361(24):2318\u20132329. Available from: https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa0908628#:~:text=Efficacy End Points,also constitute evidence of ischemia","DOI":"10.1056\/NEJMoa0908628"},{"key":"784_CR69","doi-asserted-by":"crossref","unstructured":"He L, Pappan LK, Grenache DG, Li Z, Tollefsen DM, Santoro SA, et al (2003) The contributions of the \u03b12\u03b21 integrin to vascular thrombosis in vivo. Blood [Internet] [cited 2025 Aug 26];102(10):3652\u20133657. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12893751\/","DOI":"10.1182\/blood-2003-04-1323"},{"key":"784_CR70","doi-asserted-by":"crossref","unstructured":"Hechler B, Magnenat S, Zighetti M (2005) Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4, 4\u2032, 4 \u2033, 4 \u2033. J Pharmacol Exp Ther [Internet] [cited 2014 Mar 13];314(1):232\u2013243. Available from: http:\/\/jpet.aspetjournals.org\/content\/314\/1\/232.short","DOI":"10.1124\/jpet.105.084673"},{"key":"784_CR71","doi-asserted-by":"crossref","unstructured":"Hechler B, Nonne C, Eun JR, Cattaneo M, Cazenave JP, Lanza F, et al (2006) MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2\u2032- deoxyadenosine-3\u2032,5\u2032-bisphosphate], a potent, selective, and stable antagonist of the platelet P2y1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Ther [Internet] [cited 2025 Jul 10];316(2):556\u2013563. Available from: https:\/\/jpet.aspetjournals.org\/action\/showFullText?pii=S0022356524324644","DOI":"10.1124\/jpet.105.094037"},{"key":"784_CR72","doi-asserted-by":"crossref","unstructured":"Heptinstall S, Espinosa DI, Manolopoulos P, Glenn JR, White AE, Johnson A, et al (2008) DG-041 inhibits the EP3 prostanoid receptor - a new target for inhibition of platelet function in atherothrombotic disease. Platelets [Internet] [cited 2025 Aug 26];19(8):605\u2013613. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19012178\/","DOI":"10.1080\/09537100802351073"},{"issue":"4","key":"784_CR73","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/sj.bjp.0705946","volume":"143","author":"MD Hollenberg","year":"2004","unstructured":"Hollenberg MD, Saifeddine M, Sandhu S, Houle S, Vergnolle N (2004) Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo. Br J Pharmacol 143(4):443\u2013454","journal-title":"Br J Pharmacol"},{"key":"784_CR74","doi-asserted-by":"crossref","unstructured":"Hossain MM, Pan D, Arkless KL, Rahman KM, Page CP, Authi KS, et al (2025) P2Y14 receptor activation of platelets induces Ca2+ mobilization and Rho-GTPase-dependent motility that requires an interaction with P2Y1 receptors. Br J Pharmacol [Internet] [cited 2025 Jul 10];182(13):2950\u20132967. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/40128640\/","DOI":"10.22541\/au.172956429.98898646\/v1"},{"key":"784_CR75","doi-asserted-by":"crossref","unstructured":"Hsu CC, Wu WB, Huang TF (2008) A snake venom metalloproteinase, kistomin, cleaves platelet glycoprotein VI and impairs platelet functions. J Thromb Haemost [Internet] [cited 2025 Aug 26];6(9):1578\u20131585. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18624975\/","DOI":"10.1111\/j.1538-7836.2008.03071.x"},{"key":"784_CR76","doi-asserted-by":"crossref","unstructured":"Huang JS, Dong L, Kozasa T, Le Breton GC (2007) Signaling through G\u03b113 Switch Region I Is Essential for Protease-activated Receptor 1-mediated Human Platelet Shape Change, Aggregation, and Secretion. J Biol Chem [Internet] [cited 2025 Jul 11];282(14):10210\u201310222. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S002192581957692X","DOI":"10.1074\/jbc.M605678200"},{"issue":"3","key":"784_CR77","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1083\/jcb.116.3.827","volume":"116","author":"DT Hung","year":"1992","unstructured":"Hung DT, Vu TKH, Nelken NA, Coughlin SR (1992) Thrombin-induced events in non-platelet cells are mediated by the unique proteolytic mechanism established for the cloned platelet thrombin receptor. J Cell Biol 116(3):827\u2013832","journal-title":"J Cell Biol"},{"key":"784_CR78","doi-asserted-by":"crossref","unstructured":"Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al (2001) ACC\/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology\/American Heart Association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure). Circulation [Internet] [cited 2025 Aug 26];104(24):2996\u20133007. Available from: https:\/\/www.ahajournals.org\/doi\/pdf\/10.1161\/hc4901.102568?download=true","DOI":"10.1161\/hc4901.102568"},{"key":"784_CR79","doi-asserted-by":"publisher","unstructured":"Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G (2006) Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J [Internet] [cited 2025 Jul 17];27(9):1038\u20131047. Available from: https:\/\/dx.doi.org\/https:\/\/doi.org\/10.1093\/eurheartj\/ehi754","DOI":"10.1093\/eurheartj\/ehi754"},{"key":"784_CR80","doi-asserted-by":"publisher","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J [Internet] [cited 2025 Aug 26];39(2):119\u2013177. Available from: https:\/\/doi.org\/10.1093\/eurheartj\/ehx393","DOI":"10.1093\/eurheartj\/ehx393"},{"issue":"4","key":"784_CR81","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1111\/j.1755-5922.2011.00263.x","volume":"30","author":"JA Jakubowski","year":"2012","unstructured":"Jakubowski JA, Riesmeyer JS, Close SL, Leishman AG, Erlinge D (2012) TRITON and beyond: new insights into the profile of prasugrel. Cardiovasc Ther 30(4):e174","journal-title":"Cardiovasc Ther"},{"issue":"3","key":"784_CR82","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1172\/JCI12818","volume":"108","author":"HM Jantzen","year":"2001","unstructured":"Jantzen HM, Milstone DS, Gousset L, Conley PB, Mortensen RM (2001) Impaired activation of murine platelets lacking G\u03b1i2. J Clin Invest 108(3):477\u2013483","journal-title":"J Clin Invest"},{"key":"784_CR83","doi-asserted-by":"crossref","unstructured":"Janus-Bell E, Mangin PH (2023) The relative importance of platelet integrins in hemostasis, thrombosis and beyond. Haematologica [Internet] [cited 2025 Aug 26];108(7):1734\u20131747. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36700400\/","DOI":"10.3324\/haematol.2022.282136"},{"issue":"14","key":"784_CR84","doi-asserted-by":"publisher","first-page":"8070","DOI":"10.1073\/pnas.95.14.8070","volume":"95","author":"J Jin","year":"1998","unstructured":"Jin J, Kunapuli SP (1998) Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 95(14):8070\u20138074","journal-title":"Proc Natl Acad Sci USA"},{"key":"784_CR85","doi-asserted-by":"crossref","unstructured":"Jin J, Mao Y, Thomas D, Kim S, Daniel JL, Kunapuli SP (2009) RhoA downstream of Gq and G12\/13 pathways regulates protease-activated receptor-mediated dense granule release in platelets. Biochem Pharmacol [Internet] [cited 2025 Jul 14];77(5):835\u2013844. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006295208008289","DOI":"10.1016\/j.bcp.2008.11.017"},{"key":"784_CR86","doi-asserted-by":"crossref","unstructured":"Juif P-E, Boehler M, Dobrow M, Ufer M, Dingemanse J (2019) Clinical pharmacology of the reversible and potent P2Y 12 receptor antagonist ACT-246475 after single subcutaneous administration in healthy male subjects. Pharmacokinet J Clin Pharmacol [Internet] [cited 2025 Jul 11];2019(1):123\u2013130. Available from: https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.1296","DOI":"10.1002\/jcph.1296"},{"key":"784_CR87","doi-asserted-by":"crossref","unstructured":"Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR (1999a) Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest [Internet] [cited 2025 Jul 11];103(6):879. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC408153\/","DOI":"10.1172\/JCI6042"},{"issue":"6","key":"784_CR88","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1172\/JCI6042","volume":"103","author":"ML Kahn","year":"1999","unstructured":"Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR (1999b) Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103(6):879\u2013887","journal-title":"J Clin Invest"},{"key":"784_CR89","doi-asserted-by":"crossref","unstructured":"Kassack MU, Braun K, Ganso M, Ullmann H, Nickel P, B\u00f6ing B, et al (2004) Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem [Internet] [cited 2025 Jul 17];39(4):345\u2013357. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15072843\/","DOI":"10.1016\/j.ejmech.2004.01.007"},{"key":"784_CR90","doi-asserted-by":"crossref","unstructured":"Kim S, Foster C, Lecchi A, Quinton TM, Prosser DM, Jin J, et al (2002) Protease-activated receptors 1 and 4 do not stimulate Gi signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of Gisignaling. Blood [Internet] [cited 2025 Jul 11];99(10):3629\u20133636. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497120608412","DOI":"10.1182\/blood.V99.10.3629"},{"key":"784_CR91","doi-asserted-by":"crossref","unstructured":"Kim BJ, Kwon SU, Park JH, Kim YJ, Hong KS, Wong LKS, et al (2020) Cilostazol versus aspirin in ischemic stroke patients with high-risk cerebral hemorrhage: subgroup analysis of the PICASSO trial. Stroke [Internet] [cited 2025 Aug 26];51(3):931\u2013937. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31856691\/","DOI":"10.1161\/STROKEAHA.119.023855"},{"key":"784_CR92","doi-asserted-by":"crossref","unstructured":"Koganov ES, Michelson AD, Yanachkov IB, Yanachkova MI, Wright GE, Przyklenk K, et al (2018) GLS-409, an antagonist of both P2Y1 and P2Y12, potently inhibits canine coronary artery thrombosis and reversibly inhibits human platelet activation. Sci Rep [Internet] [cited 2025 Jul 10];8(1):14529. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6162268\/","DOI":"10.1038\/s41598-018-32797-1"},{"key":"784_CR93","doi-asserted-by":"crossref","unstructured":"Kogushi M, Matsuoka T, Kawata T, Kuramochi H, Kawaguchi S, Murakami K, et al (2011) The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in Guinea pigs. Eur J Pharmacol [Internet] [cited 2025 Jul 11];657(1\u20133):131\u2013137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21300059\/","DOI":"10.1016\/j.ejphar.2011.01.058"},{"key":"784_CR94","doi-asserted-by":"crossref","unstructured":"Kuijpers MJE, Pozgajova M, Cosemans JMEM, Munnix ICA, Eckes B, Nieswandt B, et al (2007) Role of murine integrin \u03b12\u03b21 in thrombus stabilization and embolization: contribution of thromboxane A2. Thromb Haemost [Internet] [cited 2025 Aug 26];98(5):1072\u20131080. Available from: http:\/\/www.thieme-connect.com\/products\/ejournals\/html\/10.1160\/TH07-02-0089","DOI":"10.1160\/TH07-02-0089"},{"key":"784_CR95","doi-asserted-by":"crossref","unstructured":"Kuliopulos A, Gurbel PA, Rade JJ, Kimmelstiel CD, Turner SE, Bliden KP, et al (2020) PAR1 (protease-activated receptor 1) pepducin therapy targeting myocardial necrosis in coronary artery disease and acute coronary syndrome patients undergoing cardiac catheterization: a randomized, placebo-controlled, phase 2 study. Arterioscler Thromb Vasc Biol [Internet] [cited 2025 Jul 11];40(12):2990\u20133003. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33028101\/","DOI":"10.1161\/ATVBAHA.120.315168"},{"key":"784_CR96","doi-asserted-by":"crossref","unstructured":"Kumlin M, Granstr\u00f6m E (1986) Radioimmunoassay for 11-dehydro-TXB2: a method for monitoring thromboxane production in vivo. Prostaglandins [Internet] [cited 2025 Aug 26];32(5):741\u2013767. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/3823488\/","DOI":"10.1016\/0090-6980(86)90196-6"},{"key":"784_CR97","doi-asserted-by":"crossref","unstructured":"Larson MK, Chen H, Kahn ML, Taylor AM, Fabre JE, Mortensen RM, et al (2003) Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI\u2013mediated Rap1 activation in platelets. Blood [Internet] [cited 2025 Jul 14];101(4):1409\u20131415. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497120574041","DOI":"10.1182\/blood-2002-05-1533"},{"key":"784_CR98","doi-asserted-by":"crossref","unstructured":"L\u00e9on C, Freund M, Ravanat C, Baurand A, Cazenave JP, Gachet C (2001) Key role of the P2Y1 receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y1-knockout mice and mice treated with a P2Y1 antagonist. Circulation [Internet] [cited 2025 Aug 26];103(5):718\u2013723. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11156884\/","DOI":"10.1161\/01.CIR.103.5.718"},{"key":"784_CR99","doi-asserted-by":"crossref","unstructured":"Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al (2011) 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation [Internet] [cited 2025 Jul 17];124(23). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22064601\/","DOI":"10.1161\/CIR.0b013e31823ba622"},{"key":"784_CR100","doi-asserted-by":"crossref","unstructured":"Li H, Lockyer S, Concepcion A, Gong X, Takizawa H, Guertin M, et al (2007) The fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats. Arterioscler Thromb Vasc Biol [Internet] [cited 2025 Aug 26];27(5):1199\u20131205. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17322098\/","DOI":"10.1161\/ATVBAHA.107.140590"},{"key":"784_CR101","doi-asserted-by":"crossref","unstructured":"Lockyer S, Okuyama K, Begum S, Le S, Sun B, Watanabe T, et al (2006) GPVI-deficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism. Thromb Res [Internet] [cited 2025 Aug 26];118(3):371\u2013380. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16139873\/","DOI":"10.1016\/j.thromres.2005.08.001"},{"key":"784_CR102","doi-asserted-by":"crossref","unstructured":"Lopez J, Mark J, Duarte GJ, Shaban M, Sosa F, Mishra R, et al (2023) Role of genetic polymorphisms in clopidogrel response variability: a systematic review. Open Hear [Internet] [cited 2025 Jul 17];10(2):e002436. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10649851\/","DOI":"10.1136\/openhrt-2023-002436"},{"key":"784_CR103","doi-asserted-by":"crossref","unstructured":"Lova P, Paganini S, Sinigaglia F, Balduini C, Torti M (2002) A Gi-dependent Pathway Is Required for Activation of the Small GTPase Rap1B in Human Platelets. J Biol Chem [Internet] [cited 2025 Jul 14];277(14):12009\u201312015. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0021925818520202","DOI":"10.1074\/jbc.M111803200"},{"key":"784_CR104","doi-asserted-by":"crossref","unstructured":"Love BB, Biller J, Gent M (1998) Adverse haematological effects of ticlopidine. Drug Saf [Internet] [cited 2025 Jul 17];19(2):89\u201398. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9704247\/","DOI":"10.2165\/00002018-199819020-00002"},{"key":"784_CR105","doi-asserted-by":"crossref","unstructured":"Mahaut-Smith MP, Jones S, Evans RJ (2011) The P2X1 receptor and platelet function. Purinergic Signal [Internet] [cited 2013 Sep 24];7(3):341\u2013356. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3166991&tool=pmcentrez&rendertype=abstract","DOI":"10.1007\/s11302-011-9224-0"},{"key":"784_CR106","doi-asserted-by":"crossref","unstructured":"Mangin PH, Tang CJ, Bourdon C, Loyau S, Freund M, Hechler B, et al (2012) A humanized glycoprotein VI (GPVI) mouse model to assess the antithrombotic efficacies of anti-GPVI agents. J Pharmacol Exp Ther [Internet] [cited 2025 Aug 26];341(1):156\u2013163. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22238212\/","DOI":"10.1124\/jpet.111.189050"},{"issue":"2","key":"784_CR107","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-2003-40673","volume":"3","author":"S Massberg","year":"2003","unstructured":"Massberg S, Schulz C, Gawaz M (2003) Role of platelets in the pathophysiology of acute coronary syndrome. Semin Vasc Med [Internet] 3(2):147\u2013162. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15199478","journal-title":"Semin Vasc Med [Internet]"},{"key":"784_CR108","doi-asserted-by":"crossref","unstructured":"Matthews JS, Jones RL (1993) Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues. Br J Pharmacol [Internet] [cited 2025 Aug 26];108(2):363\u2013369. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/8448586\/","DOI":"10.1111\/j.1476-5381.1993.tb12810.x"},{"key":"784_CR109","doi-asserted-by":"crossref","unstructured":"Mayer CL, Koeck K, Hottmann M, Redfern A, Davis M, Barth A, et al (2023) A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease. Eur J Clin Pharmacol [Internet] [cited 2025 Aug 26];79(9):1219\u20131228. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37436495\/","DOI":"10.1007\/s00228-023-03514-3"},{"key":"784_CR110","doi-asserted-by":"crossref","unstructured":"Mazharian A, Roger S, Berrou E, Adam F, Kauskot A, Nurden P, et al (2007) Protease-activating receptor-4 induces full platelet spreading on a fibrinogen matrix: involvement of ERK2 and p38 and Ca2+ mobilization. J Biol Chem [Internet] [cited 2025 Jul 11];282(8):5478\u20135487. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S002192582068841X","DOI":"10.1074\/jbc.M609881200"},{"key":"784_CR111","doi-asserted-by":"crossref","unstructured":"Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al (2009) Cytochrome P450 genetic polymorphisms and the response to prasugrel relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation [Internet] [cited 2025 Jul 17];119(19):2553\u20132560. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19414633\/","DOI":"10.1161\/CIRCULATIONAHA.109.851949"},{"key":"784_CR112","doi-asserted-by":"crossref","unstructured":"Meng D, Luo M, Liu B (2021) The role of CLEC-2 and its ligands in thromboinflammation. Front Immunol [Internet] [cited 2025 Jul 21];12:688643. Available from: www.frontiersin.org","DOI":"10.3389\/fimmu.2021.688643"},{"issue":"7","key":"784_CR113","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1080\/09537104.2022.2088719","volume":"33","author":"S Merali","year":"2022","unstructured":"Merali S, Wang Z, Frost C, Callejo M, Hedrick M, Hui L et al (2022) New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans. Platelets 33(7):969\u2013978","journal-title":"Platelets"},{"key":"784_CR114","doi-asserted-by":"crossref","unstructured":"Merali S, Wang Z, Frost C, Meadows-Shropshire S, Hawthorne D, Yang J, et al (2023) First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants. Platelets [Internet] [cited 2025 Jul 3];34(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37394920\/","DOI":"10.1080\/09537104.2023.2222846"},{"issue":"11","key":"784_CR115","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/nm943","volume":"9","author":"A Moers","year":"2003","unstructured":"Moers A, Nieswandt B, Massberg S, Wettschureck N, Gr\u00fcner S, Konrad I et al (2003) G13 is an essential mediator of platelet activation in hemostasis and thrombosis. Nat Med 9(11):1418\u20131422","journal-title":"Nat Med"},{"key":"784_CR116","doi-asserted-by":"crossref","unstructured":"Mohammad MA, Andell P, Koul S, James S, Scherst\u00e9n F, G\u00f6tberg M, et al. (2017) Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction. Platelets [Internet] [cited 2025 Jul 17];28(4):414\u2013416. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27885888\/","DOI":"10.1080\/09537104.2016.1246714"},{"key":"784_CR117","doi-asserted-by":"crossref","unstructured":"Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al (2013) 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J [Internet] [cited 2025 Jul 17];34(38):2949\u20133003. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23996286\/","DOI":"10.1093\/eurheartj\/eht296"},{"key":"784_CR118","doi-asserted-by":"crossref","unstructured":"Moore DJ, Murdock PR, Watson JM, Faull RLM, Waldvogel HJ, Szekeres PG, et al (2003) GPR105, a novel Gi\/o-coupled UDP-glucose receptor expressed on brain glia and peripheral immune cells, is regulated by immunologic challenge: possible role in neuroimmune function. Mol Brain Res [Internet] [cited 2025 Jul 14];118(1\u20132):10\u201323. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0169328X03003309","DOI":"10.1016\/S0169-328X(03)00330-9"},{"key":"784_CR119","doi-asserted-by":"crossref","unstructured":"Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, et al (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med [Internet] [cited 2025 Jul 11];366(15):1404\u20131413. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22443427\/","DOI":"10.1056\/NEJMoa1200933"},{"key":"784_CR120","doi-asserted-by":"crossref","unstructured":"Mumaw MM, de la Fuente M, Noble DN, Nieman MT (2014) Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis. J Thromb Haemost [Internet] [cited 2025 Jul 14];12(8):1331\u20131341. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24888424\/","DOI":"10.1111\/jth.12619"},{"key":"784_CR121","doi-asserted-by":"crossref","unstructured":"Narumiya S, FitzGerald GA (2001) Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest [Internet] [cited 2025 Aug 26];108(1):25\u201330. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11435452\/","DOI":"10.1172\/JCI13455"},{"key":"784_CR122","doi-asserted-by":"crossref","unstructured":"Neri Serneri GG, Coccheri S, Marubini E, Violi F (2004) Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J [Internet] [cited 2025 Aug 26];25(20):1845\u20131852. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15474700\/","DOI":"10.1016\/j.ehj.2004.07.013"},{"key":"784_CR123","doi-asserted-by":"crossref","unstructured":"Nicolson PLR, Nock SH, Hinds J, Garcia-Quintanilla L, Smith CW, Campos J, et al (2021) Low-dose Btk inhibitors selectively block platelet activation by CLEC-2. Haematologica [Internet] [cited 2025 Jul 21];106(1):208\u2013219. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31949019\/","DOI":"10.3324\/haematol.2019.218545"},{"key":"784_CR124","doi-asserted-by":"crossref","unstructured":"Niitsu Y, Jakubowski JA, Sugidachi A, Asai F (2005) Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost [Internet] [cited 2025 Jul 14];31(2):184\u2013194. Available from: http:\/\/www.thieme-connect.de\/products\/ejournals\/html\/10.1055\/s-2005-869524","DOI":"10.1055\/s-2005-869524"},{"key":"784_CR125","doi-asserted-by":"crossref","unstructured":"Nwose EU, Yee KC (2016) Drug-disease interactions: narrative review of aspirin in gastric ulcer. Expert Opin Drug Metab Toxicol [Internet] [cited 2025 Aug 26];12(9):1081\u20131087. Available from: \/action\/showLogin?uri=%2Fdoi%2Fpdf%2F10.1080%2F17425255.2016.1201064","DOI":"10.1080\/17425255.2016.1201064"},{"key":"784_CR126","doi-asserted-by":"crossref","unstructured":"Nylander S, W\u00e5gberg F, Andersson M, Sk\u00e4rby T, Gustafsson D (2015) Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase \u03b2 inhibition and aspirin in man. J Thromb Haemost [Internet] [cited 2025 Aug 26];13(8):1494\u20131502. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26096765\/","DOI":"10.1111\/jth.13027"},{"key":"784_CR127","doi-asserted-by":"crossref","unstructured":"O\u2019Callaghan K, Kuliopulos A, Covic L (2012) Turning receptors on and off with intracellular pepducins: New insights into G-protein-coupled receptor drug development. J Biol Chem [Internet] [cited 2025 Jul 11];287(16):12787\u201312796. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22374997\/","DOI":"10.1074\/jbc.R112.355461"},{"issue":"4","key":"784_CR128","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacc.2012.11.018","volume":"61","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, De Lemos JA et al (2013) 2013 ACCF\/AHA guideline for the management of st-elevation myocardial infarction: executive summary: A report of the American college of cardiology foundation\/american heart association task force on practice guidelines. J Am Coll Cardiol 61(4):485\u2013510","journal-title":"J Am Coll Cardiol"},{"issue":"September","key":"784_CR129","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/38284","volume":"389","author":"S Offermanns","year":"1997","unstructured":"Offermanns S, Toombs CF, Hu Y, Simon MI (1997) Defective platelet activation in G \u2423 q -deficient mice. Nature 389(September):183\u2013186","journal-title":"Nature"},{"key":"784_CR130","doi-asserted-by":"crossref","unstructured":"Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, et al (2013) Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol [Internet] [cited 2025 Jul 17];61(15):1601\u20131606. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23500251\/","DOI":"10.1016\/j.jacc.2013.01.024"},{"key":"784_CR131","doi-asserted-by":"crossref","unstructured":"Patrignani P, Filabozzi P, Patrono C (1982) Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest [Internet] [cited 2025 Aug 26];69(6):1366\u20131372. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/7045161\/","DOI":"10.1172\/JCI110576"},{"key":"784_CR132","doi-asserted-by":"crossref","unstructured":"Patrignani P, Tacconelli S, Piazuelo E, Di Francesco L, Dovizio M, Sostres C, et al (2014) Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. J Thromb Haemost [Internet] [cited 2025 Aug 26];12(8):1320\u20131330. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24942808\/","DOI":"10.1111\/jth.12637"},{"key":"784_CR133","doi-asserted-by":"crossref","unstructured":"Patrono C, Rocca B (2017) Type 2 diabetes, obesity, and aspirin responsiveness. J Am Coll Cardiol [Internet] [cited 2025 Aug 26];69(6):613\u2013615. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28089179\/","DOI":"10.1016\/j.jacc.2016.11.049"},{"key":"784_CR134","doi-asserted-by":"crossref","unstructured":"Patrono C, Ciabarroni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, et al (1985) Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation [Internet] [cited 2025 Aug 26];72(6):1177\u20131184. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/3933848\/","DOI":"10.1161\/01.CIR.72.6.1177"},{"key":"784_CR135","doi-asserted-by":"crossref","unstructured":"Pedersen AK, FitzGerald GA (1984) Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med [Internet] [cited 2025 Aug 26];311(19):1206\u20131211. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/6436696\/","DOI":"10.1056\/NEJM198411083111902"},{"key":"784_CR136","doi-asserted-by":"crossref","unstructured":"Perez M, Lamothe M, Maraval C, Mirabel E, Loubat C, Planty B, et al. (2009) Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo. J Med Chem [Internet] [cited 2025 Jul 3];52(19):5826\u20135836. Available from: https:\/\/pubs.acs.org\/doi\/abs\/10.1021\/jm900553j","DOI":"10.1021\/jm900553j"},{"key":"784_CR137","doi-asserted-by":"crossref","unstructured":"Pfefferkorn JA, Choi C, Winters T, Kennedy R, Chi L, Perrin LA, et al (2008) P2Y1 receptor antagonists as novel antithrombotic agents. Bioorg Med Chem Lett [Internet] [cited 2025 Aug 26];18(11):3338\u20133343. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18445527\/","DOI":"10.1016\/j.bmcl.2008.04.028"},{"key":"784_CR138","doi-asserted-by":"crossref","unstructured":"Pitchford SC, Momi S, Giannini S, Casali L, Spina D, Page CP, et al (2005) Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. Blood [Internet] [cited 2012 Aug 13];105(5):2074\u20132081. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15528309","DOI":"10.1182\/blood-2004-06-2282"},{"key":"784_CR139","doi-asserted-by":"crossref","unstructured":"Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA [Internet] [cited 2025 Jul 17];305(11):1097\u20131105. Available from: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/646144","DOI":"10.1001\/jama.2011.290"},{"key":"784_CR140","doi-asserted-by":"crossref","unstructured":"Priestley ES, Banville J, Deon D, Dub\u00e9 L, Gagnon M, Guy J, et al (2022) Discovery of two novel antiplatelet clinical candidates (BMS-986120 and BMS-986141) that antagonize protease-activated receptor 4. J Med Chem [Internet] [cited 2025 Jul 14];65(13):8843\u20138854. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35729784\/","DOI":"10.1021\/acs.jmedchem.2c00359"},{"key":"784_CR141","doi-asserted-by":"crossref","unstructured":"Qiao JX, Wang TC, Ruel R, Thibeault C, L\u2019Heureux A, Schumacher WA, et al (2013) Conformationally constrained ortho- Anilino diaryl ureas: discovery of 1-(2-(1\u2032-Neopentylspiro[indoline-3,4\u2032-piperidine]-1-yl)phenyl) -3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist. J Med Chem [Internet] [cited 2025 Aug 26];56(22):9275\u20139295. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24164581\/","DOI":"10.1021\/jm4013906"},{"key":"784_CR142","doi-asserted-by":"crossref","unstructured":"Renda G, Tacconelli S, Capone ML, Sacchetta D, Santarelli F, Sciulli MG, et al (2006) Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther [Internet] [cited 2025 Aug 26];80(3):264\u2013274. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16952493\/","DOI":"10.1016\/j.clpt.2006.05.004"},{"key":"784_CR143","doi-asserted-by":"crossref","unstructured":"Rocca B, Patrono C (2005) Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost [Internet] [cited 2025 Aug 26];3(8):1597\u20131602. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16102024\/","DOI":"10.1111\/j.1538-7836.2005.01380.x"},{"issue":"2","key":"784_CR144","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1055\/s-0037-1615684","volume":"85","author":"MG Rolf","year":"2001","unstructured":"Rolf MG, Brearley CA, Mahaut-Smith MP (2001) Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP. Thromb Haemost [Internet]. 85(2):303\u2013308. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11246552","journal-title":"Thromb Haemost [Internet]."},{"key":"784_CR145","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020573","volume":"19","author":"GR Rudinga","year":"2018","unstructured":"Rudinga GR, Khan GJ, Kong Y (2018) Protease-Activated Receptor 4 (PAR4): a promising target for antiplatelet therapy. Int J Mol Sci 19:573. [Internet]. 2018 Feb 14 [cited 2025 Jul 14];19(2):573. Available from: https:\/\/www.mdpi.com\/1422-0067\/19\/2\/573\/htm","journal-title":"Int J Mol Sci"},{"issue":"SUPPL. 2","key":"784_CR146","first-page":"15","volume":"25","author":"M Savcic","year":"1999","unstructured":"Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R (1999) Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 25(SUPPL. 2):15\u201319","journal-title":"Semin Thromb Hemost"},{"key":"784_CR147","doi-asserted-by":"crossref","unstructured":"Savi P, Herbert JM 2005) Clopidogrel and ticlopidine: P2Y 12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost [Internet] [cited 2025 Jul 14];31(2):174\u2013183. Available from: http:\/\/www.thieme-connect.de\/products\/ejournals\/html\/10.1055\/s-2005-869523","DOI":"10.1055\/s-2005-869523"},{"key":"784_CR148","doi-asserted-by":"crossref","unstructured":"Scarborough RM, Kleiman NS, Phillips DR (1999) Platelet glycoprotein IIb\/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use? Circulation [Internet] [cited 2025 Aug 26];100(4):437\u2013444. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10421606\/","DOI":"10.1161\/01.CIR.100.4.437"},{"key":"784_CR149","doi-asserted-by":"crossref","unstructured":"Serebruany VL, Kogushi M, Dastros-Pitei D, Flather M, Bhatt DL (2009) The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost [Internet] [cited 2025 Jul 11];102(1):111\u2013119. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19572075\/","DOI":"10.1160\/TH08-12-0805"},{"key":"784_CR150","doi-asserted-by":"crossref","unstructured":"Shankar H, Kahner BN, Prabhakar J, Lakhani P, Kim S, Kunapuli SP (2006) G-protein-gated inwardly rectifying potassium channels regulate ADP-induced cPLA2 activity in platelets through Src family kinases. Blood [Internet] [cited 2012 Aug 13];108(9):3027\u20133034. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=1895524&tool=pmcentrez&rendertype=abstract","DOI":"10.1182\/blood-2006-03-010330"},{"key":"784_CR151","doi-asserted-by":"crossref","unstructured":"Shapiro MJ, Weiss EJ, Faruqi TR, Coughlin SR (2000) Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. J Biol Chem [Internet] [cited 2025 Jul 11];275(33):25216\u201325221. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0021925819620788","DOI":"10.1074\/jbc.M004589200"},{"key":"784_CR152","doi-asserted-by":"crossref","unstructured":"Sinnaeve P, Fahrni G, Schelfaut D, Spirito A, Mueller C, Frenoux JM, et al (2020) Subcutaneous selatogrel inhibits platelet aggregation in patients with acute myocardial infarction. J Am Coll Cardiol [Internet] [cited 2025 Jul 17];75(20):2588\u20132597. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0735109720347525","DOI":"10.1016\/j.jacc.2020.03.059"},{"key":"784_CR153","doi-asserted-by":"crossref","unstructured":"Smyth SS, McEver RP, Weyrich a S, Morrell CN, Hoffman MR, Arepally GM, et al (2009) Platelet functions beyond hemostasis. J Thromb Haemost [Internet] [cited 2012 Aug 8];7(11):1759\u20131766. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19691483","DOI":"10.1111\/j.1538-7836.2009.03586.x"},{"key":"784_CR154","doi-asserted-by":"crossref","unstructured":"Sostres C, Lanas A (2011) Gastrointestinal effects of aspirin. Nat Rev Gastroenterol Hepatol [Internet] [cited 2025 Aug 26];8(7):385\u2013394. Available from: https:\/\/www.nature.com\/articles\/nrgastro.2011.97","DOI":"10.1038\/nrgastro.2011.97"},{"key":"784_CR155","doi-asserted-by":"crossref","unstructured":"St\u00e4hli BE, Gebhard C, Duchatelle V, Cournoyer D, Petroni T, Tanguay JF, et al (2016) Effects of the P-selectin antagonist Inclacumab on myocardial damage after percutaneous coronary intervention according to timing of infusion: insights from the SELECT-ACS trial. J Am Heart Assoc [Internet] [cited 2025 Aug 26];5(11). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27852589\/","DOI":"10.1161\/JAHA.116.004255"},{"key":"784_CR156","doi-asserted-by":"crossref","unstructured":"Stefanini L, Roden RC, Bergmeier W (2009) CalDAG-GEFI is at the nexus of calcium-dependent platelet activation. Blood [Internet] [cited 2025 Jul 14];114(12):2506\u20132514. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497120369202","DOI":"10.1182\/blood-2009-04-218768"},{"key":"784_CR157","doi-asserted-by":"crossref","unstructured":"Stefanini L, Boulaftali Y, Ouellette TD, Holinstat M, D\u00e9sir\u00e9 L, Leblond B, et al (2012) Rap1-Rac1 circuits potentiate platelet activation. Arterioscler Thromb Vasc Biol [Internet] [cited 2012 Aug 13];32(2):434\u2013441. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3262085&tool=pmcentrez&rendertype=abstract","DOI":"10.1161\/ATVBAHA.111.239194"},{"key":"784_CR158","doi-asserted-by":"crossref","unstructured":"Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, et al (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet [Internet] [cited 2025 Jul 17];382(9892):614\u2013623. Available from: https:\/\/www.thelancet.com\/action\/showFullText?pii=S0140673613611708","DOI":"10.1016\/S0140-6736(13)61170-8"},{"key":"784_CR159","doi-asserted-by":"crossref","unstructured":"Storey RF, Gurbel PA, Berg J ten, Bernaud C, Dangas GD, Frenoux JM, et al (2020) Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. Eur Heart J [Internet] [cited 2025 Jul 17];41(33):3132\u20133140. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31994703\/","DOI":"10.1093\/eurheartj\/ehz807"},{"key":"784_CR160","doi-asserted-by":"crossref","unstructured":"Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al (2013) Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol [Internet] [cited 2025 Jul 17];62(24):2261\u20132273. Available from: \/doi\/pdf\/10.1016\/j.jacc.2013.07.101?download=true","DOI":"10.1016\/j.jacc.2013.07.101"},{"key":"784_CR161","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1016\/j.jacc.2013.03.003","volume":"61","author":"J-C Tardif","year":"2013","unstructured":"Tardif J-C, Tanguay J-F, Wright SR, Duchatelle V, Petroni T, Gr\u00e9goire JC et al (2013) Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non\u2013ST-segment elevation myocardial infarction results of the SELECT-ACS trial. J Am Coll Cardiol 61:2048\u20132055","journal-title":"J Am Coll Cardiol"},{"key":"784_CR162","doi-asserted-by":"publisher","unstructured":"Tilly P, Charles AL, Ludwig S, Slimani F, Gross S, Meilhac O, et al (2014) Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence. Cardiovasc Res [Internet] [cited 2025 Aug 26];101(3):482\u2013491. Available from: https:\/\/doi.org\/10.1093\/cvr\/cvt276","DOI":"10.1093\/cvr\/cvt276"},{"key":"784_CR163","doi-asserted-by":"crossref","unstructured":"Toyoda K, Uchiyama S, Yamaguchi T, Easton JD, Kimura K, Hoshino H, et al (2019) Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol [Internet] [cited 2025 Aug 26];18(6):539\u2013548. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31122494\/","DOI":"10.1016\/S1474-4422(19)30148-6"},{"key":"784_CR164","doi-asserted-by":"crossref","unstructured":"Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, et al (2012) Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. N Engl J Med [Internet] [cited 2025 Jul 11];366(1):20\u201333. Available from: https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa1109719","DOI":"10.1056\/NEJMoa1109719"},{"key":"784_CR165","doi-asserted-by":"crossref","unstructured":"Tullemans BME, Karel MFA, L\u00e9opold V, ten Brink MS, Baaten CCFMJ, Maas SL, et al (2021) Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function. EJHaem [Internet] [cited 2025 Jul 21];2(4):685\u2013699. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35845214\/","DOI":"10.1002\/jha2.269"},{"key":"784_CR166","doi-asserted-by":"crossref","unstructured":"Tyler HM, Saxton CAPD, Parry MJ (1981) Administration to man of UK-37,248-01, a selective inhibitor of thromboxane synthetase. Lancet [Internet] [cited 2025 Aug 26];317(8221):629\u2013632. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/6110861\/","DOI":"10.1016\/S0140-6736(81)91551-8"},{"key":"784_CR167","doi-asserted-by":"crossref","unstructured":"Uphaus T, Richards T, Weimar C, Neugebauer H, Poli S, Weissenborn K, et al (2022) Revacept, an inhibitor of platelet adhesion in symptomatic carotid stenosis: a multicenter randomized phase II trial. Stroke [Internet] [cited 2025 Aug 26];53(9):2718\u20132729. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35695006\/","DOI":"10.1161\/STROKEAHA.121.037006"},{"key":"784_CR168","doi-asserted-by":"crossref","unstructured":"van der Wicken LR, Simoons ML, Laarman GJ, van den Brand M, Nijssen KM, Dellborg M, et al (1995) Ridogrel as an adjunct to thrombolysis in acute myocardial infarction. Int J Cardiol [Internet] [cited 2025 Aug 26];52(2):125\u2013134. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/8749872\/","DOI":"10.1016\/0167-5273(95)02476-D"},{"key":"784_CR169","doi-asserted-by":"crossref","unstructured":"Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol [Internet] [cited 2025 Aug 26];231(25):232\u2013235. Available from: https:\/\/www.nature.com\/articles\/newbio231232a0","DOI":"10.1038\/newbio231232a0"},{"key":"784_CR170","doi-asserted-by":"crossref","unstructured":"Voors-Pette C, Lebozec K, Dogterom P, Jullien L, Billiald P, Ferlan P, et al (2019) Safety and tolerability, pharmacokinetics, and pharmacodynamics of ACT017, an antiplatelet GPVI (Glycoprotein VI) Fab: first-in-human healthy volunteer trial. Arterioscler Thromb Vasc Biol [Internet] [cited 2025 Aug 26];39(5):956\u2013964. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31017822\/","DOI":"10.1161\/ATVBAHA.118.312314"},{"key":"784_CR171","doi-asserted-by":"crossref","unstructured":"Voss B, McLaughlin JN, Holinstat M, Zent R, Hamm HE (2007) PAR1, but Not PAR4, activates human platelets through a Gi\/o\/Phosphoinositide-3 kinase signaling Axis. Mol Pharmacol [Internet] [cited 2025 Jul 11];71(5):1399\u20131406. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0026895X24044419","DOI":"10.1124\/mol.106.033365"},{"issue":"3","key":"784_CR172","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1160\/TH06-07-0397","volume":"97","author":"K Vretenbrant","year":"2007","unstructured":"Vretenbrant K, Ramstr\u00f6m S, Bjerke M, Lindahl TL (2007) Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development. Thromb Haemost 97(3):417\u2013424","journal-title":"Thromb Haemost"},{"key":"784_CR173","doi-asserted-by":"crossref","unstructured":"Vu TKH, Hung DT, Wheaton VI, Coughlin SR (1991) Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell [Internet] [cited 2025 Jul 14];64(6):1057\u20131068. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/009286749190261V","DOI":"10.1016\/0092-8674(91)90261-V"},{"key":"784_CR174","doi-asserted-by":"crossref","unstructured":"Wagner B, Smie\u0161ko M, Jakob RP, M\u00fchlethaler T, Cramer J, Maier T, et al (2024) Analogues of the pan-selectin antagonist rivipansel (GMI-1070). Eur J Med Chem [Internet] [cited 2025 Aug 26];272. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38728868\/","DOI":"10.1016\/j.ejmech.2024.116455"},{"key":"784_CR175","doi-asserted-by":"crossref","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med [Internet] [cited 2025 Jul 17];361(11):1045\u20131057. Available from: https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa0904327","DOI":"10.1056\/NEJMoa0904327"},{"key":"784_CR176","doi-asserted-by":"crossref","unstructured":"Wielders SJH, Bennaghmouch A, Reutelingsperger CPM, Bevers EM, Lindhout T (2007) Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists. J Thromb Haemost [Internet] [cited 2025 Jul 11];5(3):571\u2013576. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17166251\/","DOI":"10.1111\/j.1538-7836.2007.02364.x"},{"key":"784_CR177","doi-asserted-by":"crossref","unstructured":"Wilson SJ, Ismat FA, Wang Z, Cerra M, Narayan H, Raftis J, et al (2018) PAR4 (Protease-Activated Receptor 4) antagonism with BMS-986120 inhibits human ex vivo thrombus formation. Arterioscler Thromb Vasc Biol [Internet] [cited 2025 Jul 14];38(2):448\u2013456. Available from: \/doi\/pdf\/10.1161\/ATVBAHA.117.310104?download=true","DOI":"10.1161\/ATVBAHA.117.310104"},{"key":"784_CR178","doi-asserted-by":"crossref","unstructured":"Wiviott SD (2007) Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med [Internet] [cited 2014 Jan 21];357(20):2001\u20132015. Available from: http:\/\/scholar.google.com\/scholar?hl=en&btnG=Search&q=intitle:new+england+journal#2","DOI":"10.1056\/NEJMoa0706482"},{"key":"784_CR179","doi-asserted-by":"crossref","unstructured":"Wolska N, Rozalski M (2019) Blood platelet adenosine receptors as potential targets for anti-platelet therapy. Int J Mol Sci [Internet] [cited 2025 Aug 26];20(21). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31684173\/","DOI":"10.3390\/ijms20215475"},{"key":"784_CR180","doi-asserted-by":"crossref","unstructured":"Wong PC, Seiffert D, Bird JE, Watson CA, Bostwick JS, Giancarli M, et al (2017) Blockade of protease-activated receptor- 4(PAR4) provides robust antithrombotic activity with low bleeding. Sci Transl Med [Internet] [cited 2025 Jul 3];9(371). Available from: \/doi\/pdf\/10.1126\/scitranslmed.aaf5294?download=true","DOI":"10.1126\/scitranslmed.aaf5294"},{"key":"784_CR181","doi-asserted-by":"crossref","unstructured":"Woulfe D, Jiang H, Mortensen R, Yang J, Brass LF (2002) Activation of Rap1B by Gi family members in platelets. J Biol Chem [Internet] [cited 2025 Jul 14];277(26):23382\u201323390. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0021925819667116","DOI":"10.1074\/jbc.M202212200"},{"key":"784_CR182","doi-asserted-by":"crossref","unstructured":"Xu H, Tilley DG (2022) Pepducin-mediated G protein-coupled receptor signaling in the cardiovascular system. J Cardiovasc Pharmacol [Internet] [cited 2025 Jul 3];80(3):378\u2013385. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35170495\/","DOI":"10.1097\/FJC.0000000000001236"},{"key":"784_CR183","doi-asserted-by":"crossref","unstructured":"Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, et al (1998) Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA [Internet] [cited 2025 Jul 11];95(12):6642\u20136646. Available from: https:\/\/www.pnas.org\/doi\/pdf\/10.1073\/pnas.95.12.6642","DOI":"10.1073\/pnas.95.12.6642"},{"key":"784_CR184","doi-asserted-by":"crossref","unstructured":"Xu H, Bonaca MP, Goodrich E, Scirica BM, Morrow DA (2021) Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2\u00b0P-TIMI 50 trial. Eur Heart J Acute Cardiovasc Care [Internet] [cited 2025 Jul 11];10(2):190\u2013199. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31642690\/","DOI":"10.1177\/2048872619883354"},{"key":"784_CR185","doi-asserted-by":"crossref","unstructured":"Yang J, Wu J, Jiang H, Mortensen R, Austin S, Manning DR, et al (2002) Signaling through Gi Family Members in Platelets: redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem [Internet] [cited 2025 Jul 14];277(48):46035\u201346042. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S002192581933203X","DOI":"10.1074\/jbc.M208519200"},{"key":"784_CR186","unstructured":"Zhang C, Srinivasan Y, Arlow DH, Fung JJ, Palmer D, Zheng Y, et al (2012a) High-resolution crystal structure of human protease-activated receptor 1 bound to the antagonist vorapaxar. Nature [Internet] [cited 2025 Jul 11];492(7429):387. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3531875\/"},{"issue":"1","key":"784_CR187","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1161\/CIRCULATIONAHA.112.091918","volume":"26","author":"P Zhang","year":"2012","unstructured":"Zhang P, Gruber A, Kasuda S, Kimmelstiel C, O\u2019Callaghan K, Cox DH et al (2012b) Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation 26(1):83\u201391","journal-title":"Circulation"},{"key":"784_CR188","doi-asserted-by":"crossref","unstructured":"Zheng SL, Roddick AJ (2019) Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA - J Am Med Assoc [Internet] [cited 2025 Aug 26];321(3):277\u2013287. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30667501\/","DOI":"10.1001\/jama.2018.20578"},{"key":"784_CR189","doi-asserted-by":"crossref","unstructured":"Zheng B, Li J, Jiang J, Xiang D, Chen Y, Yu Z, et al (2021) Safety and efficacy of a platelet glycoprotein Ib inhibitor for patients with non-ST segment elevation myocardial infarction: a phase Ib\/IIa study. Pharmacotherapy [Internet] [cited 2025 Aug 26];41(10):828\u2013836. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34478577\/","DOI":"10.1002\/phar.2620"}],"container-title":["Handbook of Experimental Pharmacology","Antithrombotic and Antiplatelet Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2025_784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T18:42:36Z","timestamp":1777056156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2025_784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9783032228994","9783032229007"],"references-count":189,"URL":"https:\/\/doi.org\/10.1007\/164_2025_784","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"30 January 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}